Robotic-assisted partial nephrectomy using the HugoTM robotic-assisted surgery platform

Initial experience and insights

Authors

  • Adam Bobrowski Division of Urology, Department of Surgery, University of Toronto, Toronto, ON, Canada https://orcid.org/0000-0002-8998-8830
  • William Wu Division of Urology, University Health Network, Toronto, ON, Canada
  • Chelsea Angeles Division of Urology, University Health Network, Toronto, ON, Canada
  • Simon Czajkowski Cummings School of Medicine, University of Calgary, Calgary, AB, Canada
  • Jason Y. Lee Division of Urology, University Health Network, Toronto, ON, Canada

DOI:

https://doi.org/10.5489/cuaj.8951

Keywords:

Nephrectomy, Renal Cell Carcinoma, Kidney Neoplasm, Robotic Surgical Procedures, Minimally Invasive Surgical Procedures

Abstract

INTRODUCTION: Robotic-assisted surgery (RAS) is a vital modality in the armamentarium of minimally invasive surgeons. The Hugo™ RAS system (Medtronic®) is one of the newest platforms on the market and has little surgical outcomes data. Herein, we describe our early experience performing robotic-assisted partial nephrectomy (RAPNx) with the Hugo™ RAS platform.

METHODS: We conducted a retrospective review of patients who underwent a RAPNx with the Hugo™ RAS platform between April and December 2023 at the University Health Network in Toronto, ON. One surgeon performed all procedures using a three-arm transperitoneal approach. Anesthetic, operative, and pathologic reports were assessed to collect pre-, intra- and postoperative variables.

RESULTS: Eleven patients were included. The mean age was 51 years, 45.0% were female, and 63.6% had a right-sided mass. Mean tumor size was 2.9 cm. Mean warm ischemia time was 18.9 minutes (standard deviation [SD] 7.12) and mean estimated blood loss was 179 ml (SD 63.6). Mean robot docking time was 232 seconds (SD 106.5), mean total console time was 93 minutes (SD 21.4), and mean total operative time was 165.6 minutes (SD 34.1). There were no intraoperative complications. On pathology review, most tumors were a clear-cell variant (72.7%) and staged pT1a (81.8%). All margins were negative. One patient sustained a port site infection.

CONCLUSIONS: This is the first North American case series using the Hugo™ RAS platform for RAPNx. Our findings underscore that the platform is safe and effective for performing RAPNx with comparable outcomes to other robotic platforms.

Downloads

Download data is not yet available.

Downloads

Published

2024-12-09

How to Cite

Bobrowski, A., Wu, W., Angeles, C., Czajkowski, S., & Lee, J. Y. (2024). Robotic-assisted partial nephrectomy using the HugoTM robotic-assisted surgery platform: Initial experience and insights . Canadian Urological Association Journal, 19(4), 110–5. https://doi.org/10.5489/cuaj.8951

Issue

Vol. 19 No. 4 (2025): CUAJ April

Section

Original Research

License

You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:

  • Post the Article on any Web site
  • Translate or authorize a translation of the Article
  • Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
  • Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.

The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.

You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.

The CUA also requires you to warrant the following:

  • That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
  • That all individuals who have made a substantive contribution to the article are acknowledged;
  • That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
  • That the Article does not libel or violate the privacy rights of any third party.